EP1406583A2 - Körperpflegemittel enthaltend folsäure - Google Patents

Körperpflegemittel enthaltend folsäure

Info

Publication number
EP1406583A2
EP1406583A2 EP02746199A EP02746199A EP1406583A2 EP 1406583 A2 EP1406583 A2 EP 1406583A2 EP 02746199 A EP02746199 A EP 02746199A EP 02746199 A EP02746199 A EP 02746199A EP 1406583 A2 EP1406583 A2 EP 1406583A2
Authority
EP
European Patent Office
Prior art keywords
oil
folic acid
water emulsion
phase
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02746199A
Other languages
English (en)
French (fr)
Inventor
Elzbieta Brand-Garnys
Astrid Christina Heijmeriks
Ursula Maczkiewitz
Peter Lersch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evonik Operations GmbH
Original Assignee
TH Goldschmidt AG
Goldschmidt GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TH Goldschmidt AG, Goldschmidt GmbH filed Critical TH Goldschmidt AG
Priority to EP02746199A priority Critical patent/EP1406583A2/de
Publication of EP1406583A2 publication Critical patent/EP1406583A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0295—Liquid crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/062—Oil-in-water emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations

Definitions

  • the invention concerns an oil-in water emulsion, said oil-in-water emulsion for cosmetical use, a process to prepare said emulsion, a premix for said oil-in-water emulsion and a two chamber dispenser.
  • the US Food and Nutrition Board has suggested to increase the recommended folate intake for adults to 400 micrograms per day from the previous 200 microgram per day.
  • the reason for the widespread occurrence of folate deficiency is the absence in humans of enzymes to synthesize folate from the basic building blocks so that there is a total dependence upon dietary intake.
  • fruit and vegetables contain relatively high
  • topically applied folate or folic acid reports describing the effects of topically applied folate or folic acid. It is even unknown if topically applied folates or folic acid can penetrate the skin to add to the subcutaneous folate levels.
  • Folate or its synthetic precursor folic acid are also known as vitamin B9 and these compounds thus belong to the group of B-vitamins. Folate (i.e. vitamin B9) plays an important role in the one- carbon mechanism required for DNA and RNA synthesis
  • vitamin B12 cyanobalamin
  • vitamin B6 pyridoxine
  • vitamin B12 plays a crucial role and like folate, vitamin B 12 deficiencies have also been linked with inadequate DNA metabolism and increased chromosome damages (J Sci Food Agric 80: 795-824 (2000)).
  • Vitamin B6 is involved as a cofactor in the enzymatic transformation of homocysteine
  • vitamin B3 (niacin)
  • B-vitamins such as vitamin B5 (panthothenic acid) and vitamin B8 (biotin or
  • vitamin H have no known direct effects on the metabolism of DNA, but exhibit several beneficial topical effects if incorporated in personal care products.
  • proven benefits of vitamin B5 include skin moisturisation and anti-
  • Vitamin B8 is associated with the process of cell development and lipid metabolism. In personal care
  • topically applied vitamins are capable of normalizing the microbiological flora of the skin, for example in relation to the
  • At least one of the immiscible liquids is present in a
  • amphiphilic products are usually referred to as "emulsifiers”.
  • Multi-phase systems are usually stabilised by self-aggregation of the amphiphilic products.
  • This self-aggregation is characterised by a structured agglomeration of the amphiphilic products to such an extent that hydrophilic-hydrophobic repulsion is
  • Emulsifiers an Alternative to Traditional Emulsifiers based on Stability of Multi-Phase
  • micelles Such micelles are frequently encountered in wash-active products such as shampoos, detergents, etc. and are not relevant within the scope of the present invention.
  • Such plate-like structures are characterised by a double layer of head-tail/ tail-head oriented amphiphilic molecules that physically separate the dispersed droplets and thus stabilise the emulsion.
  • liquid crystalline double layer formed is possible using advanced methods but is usually done by visually estimating the concentration of the Maltese crosses or oily streaks
  • consistency enhancers such as fatty acids or hydroxy fatty acids
  • the liquid crystalline double layer is blanketed with a suitable rheological additive usually a hydrocolloid.
  • a suitable rheological additive usually a hydrocolloid.
  • the interaction by and between the liquid crystalline double layer and the hydrocolloid is based on Vanderwaals interactions.
  • Suitable hydrocolloids are polysaccharides such as tree and
  • shrub exudates like gum arabic, fermentation products such as xanthan gum, seed extracts such as guar gum, seaweed extracts such as alginates, plant derived materials such as pectins, starches, cellulose or cellulose derivatives such as hydroxy ethyl cellulose.
  • synthetic rheological additives such acrylic homo- and copolymers, and
  • modified clays such as smectites, hectorites, bentonites, hydrated silica and fumed silica
  • Personal care products and especially skin care products are usually based upon very
  • Water (O/W) emulsions are typically prepared by dissolving the hydrocolloid as well as
  • the other water soluble components for example water-soluble vitamins belonging to the group of B-vitamins, in the water phase.
  • the suitable emulsifiers are dissolved in the water phase.
  • oil phase and then the oil phase is added to the water phase (usually at elevated
  • a suitable homogeniser such as a rotor-stator mixer at high velocity.
  • folic acid cannot be incorporated in a stable and bio-available form. In later life the epidermal skin can reveal several types of imperfections such as general
  • blemishes can include small spots with a
  • erythrosis as well as epidermal lesions known as maculae, naevi, ulcers, scales and local hyperkeratosis. Blemishes may also occur on the scalp. However, blemishes occur, or
  • B-vitamins are useful to treat tactility or visibility of superficial skin blemishes or to treat tactility or visibility of
  • the invention provides therefore an oil-in-water emulsion of the type stated in the preamble comprising substantially dissolved folic acid and a hydrocolloid, with the proviso that this oil-in-water emulsion does not contain L-arginin or derivatives thereof.
  • the folic acid is preferably present in an amount of 0.01 - 0.5 wt%, preferably in an
  • hydrocolloid is preferably selected of the
  • the hydrocolloid is present in an amount of of 0.01 - 2 wt%, more preferably in an amount of 0.1 - 0.5 wt%.
  • the oil-in-water emulsion comprises as further additive one or more amino acids, preferably selected from the group consisting of glutamate, methionine, cysteine
  • the oil-in-water emulsion is especially suitable for cosmetical use, more especially for topical use, preferably for one or more of the following treatments:
  • the present invention provides furthermore a process to prepare an oil-in-water
  • emulsion according to the invention by a. preparing an oil phase by heating cosmetically acceptable oil or a mixture of
  • cosmetically acceptable oils at least one cosmetically acceptable emulsifier and at least one cosmetically acceptable polar wax to a temperature of about 50 - 90 °C, preferably
  • hydrocolloid in water and heating this dispersion to about 50 - 90 °C, preferably
  • preparing an aqueous folic acid phase by dissolving folic acid either in water adjusted at a pH of 0.5 - 3 or in water with creatinine in an amount of at least 3 times the amount of folic acid and
  • step c preferably the amount of creatinine applied is at least 1 gr per 0.5 g of
  • folic acid in 10 gr of water and the amount of ureum applied is at least 5 gr per 0,5 gr of folic acid in 10 gr of water.
  • Acidification occurs preferably by using an acid selected from the group consisting of citric acid, acetic acid, phosphoric acid or hydrochloric acid.
  • the oil phase is prepared comprising oil selected from the group consisting of
  • an ester oil a mineral oil, a natural triglyceride, a silicone oil, or a mixture thereof. More
  • oil phase is prepared comprising an emulsifier selected from the group
  • oil phase consisting of an alkoxylated fatty alcohol, a silicone polyether, a fatty acid ester of a polyglycerin or a carbohydrate, or a mixture thereof.
  • oil phase is prepared comprising as polar wax a fatty alcohol.
  • aqueous hydrocolloid phase is prepared from a hydrocolloid selected
  • the invention also provides a premix for the oil-in water emulsion according to the invention consisting substantially of a solution of folic acid at a pH of about 0.5 - 3 or
  • the invention provides a two-chamber dispenser with in one chamber an oil-in- water emulsion according to the present invention and in the second chamber one or
  • Personal care products are products that are applied to skin, hair, nails and mucous
  • Emulsions are defined as systems of at least two mutually immiscible liquids whereby at least one of these liquids is present in a finely divided state in at least one of
  • Oil-in-Water (O/W) emulsions are considered in which the water phase is the continuous phase and the oil phase the dispersed phase.
  • oils are suitable for the incorporation into O/W emulsions intended for personal
  • Examples are mono- or diesters of linear or branched mono- or
  • acids as for example methyl laureate, oleate and erucate as well as isopropyl palmitate, myristate, stearate and isopropyloleate also form suitable oils.
  • suitable mono esters are for example n-butylstearate, n-hexyllaureate, n-decyloleate, isooctylstearate,
  • Di-n-butyl adipate, di-(2-hehexyldecyl)-succinate, ethyleneglycoldioleate, propylene glycol-di-(2-ethylhexanoate and butane diol-di-isostearate can also be used as well as mineral oils, sillicon oils and naturally occurring oils such as olive, sunflower,
  • structures include ethoxylated/propoxylated fatty alcohols, ethers of fatty alcohols and
  • copolymers of ethylene oxide, propylene oxide, tetrahydrofuran, and combinations thereof are also included.
  • electrically charged emulsifiers form a liquid crystalline bilayer such as lecithins and kephalins (1,2-diacyl glycerophosphates, as a condensate with serine,
  • inositol, choline or monoethanolamine or other phospholipids or sphingolipids or
  • glycolipids are glycolipids.
  • these foreign chemical compounds should preferably be dissolved in the liquid crystalline double layer. For example, it has been shown that
  • corticosteroids can be dissolved in a double layer formed by lecithin.
  • hydrophilic substances with a conflicting dielectricum may molecularly dissolve in particular double layers while substances with a non-conflicting dielectricum may not.
  • hydrophilic substances with a conflicting dielectricum may molecularly dissolve in particular double layers while substances with a non-conflicting dielectricum may not.
  • dissolved in the liquid crystalline double layer comprise alkyl glucosides such lauryl,
  • polyglyceryl esters and ethers of common fatty acids and fatty alcohols Preferred
  • emulsifiers enabling the formation of emulsions containing dissolved folic acid are fatty acid esters of polyglycerin or carbohydrates, ethoxylated fatty alcohols and silicone polyethers. Most preferred emulsifyers enabling the formation of emulsions containing
  • the folic acid added can be substantially dissolved in the liquid crystalline layers of the emulsion.
  • substantially dissolved meaning that less than 10 %, preferably less than 1 % of folic acid added is visible as crystallites in the final emulsion as judged by optical microscopy (magnification 200-400 x) in combination with polarized light.
  • a liquid phase is prepared in which the folic acid is properly dissolved.
  • folic acid is unsoluble in water but can be dissolved to some extent in boiling water or under alkaline or acidic conditions.
  • an aqueous phase can be prepared under mildly acidic conditions and
  • processing temperatures between 50 to 90 degrees C, preferably 60 to 80 degrees C that allows the incorporation of relatively high amounts of folic acid in a substantially dissolved form into O/W emulsions. More surprisingly we have found that the
  • incorporation of either urea or creatinine into the aqueous phase allows the dissolution of high amounts of folic acid under near neutral pH conditions enabling the preparation of O/W emulsions containing substantially dissolved folic acid. For example dissolving
  • O/W emulsions according to the invention may incorporate folic acid in quantities that range from 0.1 microgram g emulsion to 5
  • liquid crystalline double layers holding the folic acid and formed by the selected emulsifiers are reinforced by a suitable
  • hydrocolloid or a mixture of suitable hydrocolloids.
  • suitable hydrocolloids include
  • polysaccharides such as tree and shrub exudates (karaya gum, tragacanth gum, gum arabic, gum ghatti, etc), fermentation products such as xanthan gum, seed extracts such as guar gum (and derivatives), locust bean gum, quince seed gum, psyllium seed gum,
  • seaweed extracts such as alginates (and esters thereof) and
  • carrageenan (various forms), agar-agar, pectins, starches, cellulose derivatives such as
  • methylcellulose hydroxyethylcellulose, hydroxypropyl methylcellulose.
  • synthetic hydrocolloids such acrylic homo- and copolymers, and modified clays such as smectites, hectorites, bentonites, hydrated silica and fumed silica are useful. Preferred
  • carbomers are carbomers, alkyl modified carbomers, xanthan gum, locust bean gum,
  • hydroxyethylcellulose hydroxypropylcellulose and hydroxypropyl methylcellulose.
  • concentration of thesehydrocolloids may vary depending on the nature of the
  • hydrocolloid chosen but typically ranges from 0.01-2.00 %.
  • an oil phase such as mineral oil, isopropyl stearate, isopropyl palmitate, caprylic/capric triglyceride, cyclopentasiloxane( 1-40%), a selected emulsifier
  • cetearyl glucoside/cetearyl alcohol 0.5-15%, preferably 2.5%) and folic acid
  • compositions are added to stabilise the emulsion or to improve the performance of the final personal care product, for example consistency enhancers such as fatty alcohols or hydroxy fatty alcohols of 12 to 22,
  • a suitable hydrocolloid such as xanthan gum (0.05-
  • smoothing of the skin such as mineral hydrocarbons, fatty acid esters, polydimethylsiloxanes, vegetable oils, ethoxylated or propoxylated fatty alcohols, benzoic acid esters etc (0.1-20 %), humectants such as alcohols and/or polyols such as
  • glycols glycerol, sorbitol, methylglucose, polyglycerol or polysaccharides and
  • ethoxylates/ propoxylates thereof 0.05-20%), cosmetically acceptable preservatives such as parabene cocktails supported by co-preservatives (0.1-1.0 %) and cosmetic actives such as vitamins, UV filters such as octylmethoxycinnamates or titanium
  • DNA repair enzymes such as photolyases or bacteriophage T4 endonuclease V (Jean Krutmann, Skin Pharmacol Appl Skin Physiol
  • the emulsion can be made in a temperature range of 30-90 °C, preferably 55-80 °C, in a pH range of 4.0-9.0,
  • the emulsion obtained will contain large numbers of liquid crystalline
  • samples of the emulsions have been applied daily and for extended periods of time on the skin of a
  • verruceous tissue was also found to decline as the result of the regular exposure to the folic acid containing emulsion according to the invention.
  • synergistically working vitamins are the water-soluble vitamins of the B-group which include vitamin
  • B12 cyanobalamin
  • vitamin B6 pyridoxol
  • vitamin B3 niacin
  • vitamin B5 panthothenic acid or its precursor panthenol
  • vitamin B8 biotin
  • vitamins B3, B6 and B 12 are vitamins B3, B6 and B 12. Suitable concentrations of these vitamins in the end
  • vitamins into the liquid crystalline double layer i.e. these vitamins can be added to the
  • methionine, cysteine and serine can be added for improved performance of the final product.
  • Arlatone, Arlamol and Estol are registered trademarks of Uniqema; Glucam is a registered trademark of Union Carbide c/o Amerchol; Phenonip & Nipaguard are registered trademarks of NIP A Laboratories; Rhodicare is a registered trademark of Rhodia; Myritol and Lanette are registered trademarks of Cognis; Dow Corning is a registered trademark of Dow Chemical. Folic acid was obtained from E.Merck, Darmstadt, Germany.
  • phase A ARLATONE 2121 is mixed with water and heated to 85-90°C. A gel will be formed. The gel is cooled to 60°C. Propylene glycol and Glucam E20 are added and mixed until homogeneous. Phenonip and Nipaguard DCB are added.
  • Rhodicare D is dispersed in water and heated to 60°C while stirring gently.
  • Phase B then added to phase A and stirred until homogeneous. The temperature is maintained at 60°C.
  • Phase C is prepared by heating the folic acid plus the 10% citric acid to 80 degrees and then adding the demineralised water at a temperature of 60°C while mixing gently. Phase C is then added to phase ⁇ A+B ⁇ while stirring gently. The gel is monitored by microscope (100-400times magnification) for the absence of crystallites of folic acid.
  • Phase D is prepared by heating and mixing to 60°C. Phase D is then added to phase ⁇ A+B+C ⁇ without mixing. The mixture is homogenized during 20 seconds and the emulsion is subsequently stirred until ambient temperature has been reached.
  • the emulsion obtained After cooling down the emulsion obtained has a viscosity of 12.500 cPs Brookfield viscosity (S5; 20 rpm; 20°C) and a pH of 6,15.
  • the emulsion is evaluated microscopically for the absence of crystallites and the presence of "Maltese crosses". If crystallites are present, step 4 of the procedure has not been performed up to the requirements and it is recommended to increase the temperature of phase C and phase ⁇ A+B ⁇ just before mixing to 80 degrees C.
  • the solution of 10% citric acid can be replaced by dilute phosphoric or hydrochloric acid to obtain a clear phase C at a pH of 0.5 to 1.0. If no or little Maltese crosses can be observed, the liquid crystalline phase has not been formed.
  • TNCI Caprylic/Capric Triglyceride ARLAMOL® E 4.00 %
  • Phase-F PRICERINE 9099 5.00 %
  • Brij, Arlamol, Pricerine and Estol are registered trademarks of Uniqema; Glucam is a registered trademark of Union Carbide c/o Amerchol ; Phenonip & Nipaguard are registered trademarks of NIPA Laboratories; Carbopol is a registered trademark of BF Goodrich; Myritol and Lanette are registered trademarks of Cognis; Dow Coming is a registered trademark of Dow Chemical. Folic acid was obtained from E.Merck, Darmstadt, Germany.
  • PROCEDURE
  • phase A BRIJ 721 is mixed with water and heated to 75-80°C. A low viscous semi-transparent solution will be formed. The solution is cooled to 60°C. Propylene glycol and Glucam E20 are added and mixed until homogeneous. Phenonip and Nipaguard DCB are added.
  • Rhodicare D is dispersed in water, and subsequently Carbopol
  • ETD2020 and Carbopol 2050 are dispersed. The dispersion is heated to 60°C while stirring gently. 2 Phase B is added to phase A and stirred until homogeneous. The temperature is maintained at 60°C.
  • Phase C is prepared by heating the folic acid plus the 10% citric acid to 80 degrees and then adding the demineralised water at a temperature of 60°C while mixing gently. Phase C is added to phase ⁇ A+B ⁇ while stirring gently. The mixture is homogenized during 20 seconds and the emulsion is subsequently stirred for 5 minutes, and phase D is added. The temperature of the emulsion is maintained at 60°C while stirring during 30 minutes.
  • phase E The sodium hydroxide solution (phase E) is added to neutralize the acrylic resins present.
  • phase F is added while stirring gently.
  • the emulsion is cooled to ambient temperature while mixing gently.
  • PRODUCT EVALUATION The emulsion obtained has a viscosity of 10.300 cPs Brookfield viscosity (S5; 20 rpm; 20°C) and a pH of 5,80.
  • the emulsion is evaluated microscopically for the absence of crystallites and the occurrence of Maltese crosses. If crystallites are present, step 4 of the procedure has not been performed up to the requirements and it is recommended to increase the temperature of phase C and phase ⁇ A+B ⁇ just before mixing to 80 degrees C.
  • the solution of 10% citric acid can be replaced by dilute phosphoric or hydrochloric acid to obtain a clear phase C at a pH of 0.5 to 1.0. If no or few Maltese crosses are observed, the liquid crystalline phase has not been formed.
  • EXAMPLE 3 The following formula illustrates the composition and production of a cosmetic formulation in which folic acid has been dissolved in an aqueous phase using creatinine
  • ABIL ® , TEGINACID ® , TEGO ® ' TEGIN ® and COSMOCAIR ® are registered trademarks of Goldschmidt AG, Essen, Germany.
  • PROCEDURE 1. Phase A and Phase B are heated to 70 °C and combined without stirring.
  • the stability of the emulsion can be improved by increasing the concentration of either the polar wax or the hydrocolloid or both.
  • the tactility as well as colour of the spots was found to be reduced and much more in line with the touch and complexion of the surrounding, normal skin.
  • the epidermis of the skin exhibited a softer touch and featured a visibly less scaly character.
  • provitamin B5 in the aqueous phase A male person of 48 years old with a hyperkeratotic area on one of his hands resulting from the handling of benzedine powder for a limited period of time some 30 years ago, was asked to use an emulsion according to the formula as provided in Example 2.
  • Example 1 A male person of 52 years old with a small verrucous outgrowth on his face was asked to use an emulsion according to the formula provided in Example 1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Dispersion Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP02746199A 2001-07-10 2002-07-09 Körperpflegemittel enthaltend folsäure Withdrawn EP1406583A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP02746199A EP1406583A2 (de) 2001-07-10 2002-07-09 Körperpflegemittel enthaltend folsäure

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP01202646A EP1275369A1 (de) 2001-07-10 2001-07-10 Folsäure enthaltende Körperpflegemittel
EP01202646 2001-07-10
EP02746199A EP1406583A2 (de) 2001-07-10 2002-07-09 Körperpflegemittel enthaltend folsäure
PCT/NL2002/000449 WO2003005974A2 (en) 2001-07-10 2002-07-09 Folic acid containing personal care product

Publications (1)

Publication Number Publication Date
EP1406583A2 true EP1406583A2 (de) 2004-04-14

Family

ID=8180625

Family Applications (2)

Application Number Title Priority Date Filing Date
EP01202646A Withdrawn EP1275369A1 (de) 2001-07-10 2001-07-10 Folsäure enthaltende Körperpflegemittel
EP02746199A Withdrawn EP1406583A2 (de) 2001-07-10 2002-07-09 Körperpflegemittel enthaltend folsäure

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP01202646A Withdrawn EP1275369A1 (de) 2001-07-10 2001-07-10 Folsäure enthaltende Körperpflegemittel

Country Status (6)

Country Link
EP (2) EP1275369A1 (de)
JP (1) JP2004536837A (de)
CN (1) CN1525848A (de)
AU (1) AU2002315952A1 (de)
BR (1) BR0210890A (de)
WO (1) WO2003005974A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006032413A1 (de) * 2006-07-13 2008-01-17 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Folsäure und einem oder mehreren Polyolen
CN101862274B (zh) * 2010-05-28 2012-06-06 骆琦 一种含有叶酸的护肤品组合物及其制备方法
CN101862275B (zh) * 2010-05-28 2011-09-28 骆琦 一种含有叶酸的清洁护肤品组合物及其制备方法
EP3775116A4 (de) * 2018-04-05 2022-03-23 Bausch Health Ireland Limited Systeme zur abgabe einer polymeremulsion
CN112336644A (zh) * 2019-08-07 2021-02-09 北京大学 叶酸-金属离子组合物及其制备方法和在防晒中的用途
CN115414274B (zh) * 2022-09-29 2024-09-10 宁波博雅格致健康科技有限公司 叶酸银离子材料在制备头皮护理组合物中的应用、头皮护理组合物和制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6224M (de) * 1966-08-23 1968-08-05
JPS59173124A (ja) * 1983-03-19 1984-10-01 Shiseido Co Ltd 乳化組成物
JPH0748991B2 (ja) * 1984-08-29 1995-05-31 日本油脂株式会社 経管栄養組成物
LU87145A1 (fr) * 1988-02-26 1989-09-20 Oreal Methode pour ameliorer l'aspect esthetique de la peau a l'aide de melanges polyvitaminiques
DE4341001A1 (de) * 1993-12-02 1995-06-08 Beiersdorf Ag Topische Zubereitungen mit einem Gehalt an L-Arginin
DE4405545A1 (de) * 1994-02-22 1995-08-31 Dietl Hans Fettlösliche Vitamine enthaltende Zubereitung zur oralen Applikation
EP0704199B1 (de) * 1994-04-20 2003-03-19 Mitsubishi Pharma Corporation Transfusionsbehälter,transfusionspräparat sowie umfassendes,vitamine enthaltendes,kaloriereiches präparat
DE10036797A1 (de) * 2000-07-28 2002-02-07 Beiersdorf Ag Verwendung von Kombinationen mit einem Gehalt an Carnitinen
DE10062401A1 (de) * 2000-12-14 2002-06-20 Beiersdorf Ag Verwendung von Folsäure und/oder deren Derivaten zur Herstellung kosmetischer oder dermatologischer Zubereitungen zur Prophylaxe von Schäden an der hauteigenen DNA und/oder zur Reparatur bereits eingetretener Schäden an der hauteigenen DNA

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03005974A3 *

Also Published As

Publication number Publication date
EP1275369A1 (de) 2003-01-15
WO2003005974A2 (en) 2003-01-23
AU2002315952A1 (en) 2003-01-29
JP2004536837A (ja) 2004-12-09
CN1525848A (zh) 2004-09-01
WO2003005974A3 (en) 2003-09-04
BR0210890A (pt) 2004-06-22

Similar Documents

Publication Publication Date Title
KR100736842B1 (ko) 에탄올아민 유도체 및 유기 금속 염을 포함하는 조성물
US6468564B1 (en) Topical compositions containing lotus for skin treatment
US20070092469A1 (en) Topically applied Glucosamine Sulfate and all its related, precursor, and derivative compounds significantly increases the skin's natural produciton of hyaluronic acid for the rejuvenation of healthier younger-looking skin; while PhosphatidylCholine is required to replace its deficiency caused by topical Dimethylaminoethanol (DMAE)
ES2222671T3 (es) Utilizacion de al menos un hidroxiestilbeno en una composicion destinada a favorecer la descamacion de la piel.
JP5093998B2 (ja) 色素沈着予防又は改善剤
WO1998033471A1 (en) Non-irritating composition for treating acne and other skin conditions
KR20090112630A (ko) 항주름제 및 ａｄａｍ 저해제
JP2937446B2 (ja) 白髪防止黒化剤
JP4518367B2 (ja) 毛穴縮小剤
JP5766258B2 (ja) 色素沈着予防又は改善剤
WO2008078154A2 (en) Skin lightening composition for hyperpigmented skin
JP2025083496A (ja) スクロースエステル及び溶媒を含む化粧品組成物
US20030095991A1 (en) Treatment for skin
EP1192939A2 (de) Verfahren zur Verminderung von Inflammation und Erytheme
WO2003005974A2 (en) Folic acid containing personal care product
JP2006213696A (ja) 皮膚外用剤
JP2004196666A (ja) スティギングを抑制した化粧料
JP4828077B2 (ja) 皮膚外用剤
US20070190173A1 (en) Antioxidant skin compositions and methods of production of the same
KR100656807B1 (ko) 구연산, 아연 및 아르기닌으로 이루어진 팽창선조 예방 및치료용 조성물
CN116546966B (zh) 制造包含蔗糖酯和溶剂的化妆品组合物的方法
EP0881896A1 (de) Hautbehandlungsmittel mit salicylsäureestern und retinoiden
JP2532495B2 (ja) 皮膚化粧料
JP3556479B2 (ja) 皮膚プレトリートメント剤
JP4950390B2 (ja) 皮膚外用剤

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17P Request for examination filed

Effective date: 20040304

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060201